Therapeutic treatment of breast cancer based on c-MAF status
AssigneeInbiomotion S.L.
InventorsWalter Martin Gregory, Juan Carlos Tercero, Roger Gomis, Robert E. Coleman
Life of this patent
Estimating the term…
Abstract
The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
Claims19
A method for the treatment of a subject having breast cancer which comprises:
- i) quantifying the c-MAF gene copy number, amplification, or gain in a tumor sample of said subject and
- ii) comparing the copy number, amplification, or gain obtained in i) with a reference value, wherein the reference value is less than 2.5 copies of the c-MAF gene as measured using FISH,
- wherein said subject has not increased copy number, amplification, or gain with respect to said reference value, and administering to said subject a therapy selected from the group consisting of:
- clodronate, ibandronate, and zoledronic acid.
A method for the treatment of bone metastasis in a subject having breast cancer comprising determining that said subject has non increased c-MAF amplification, copy number or gain in a tumor sample with respect to a control sample and administering to said subject an agent capable of preventing or inhibiting bone remodeling or improving disease free survival or overall survival, wherein the agent capable of preventing or inhibiting bone remodeling or improving disease free survival or overall survival is selected from the group consisting of:
- clodronate, ibandronate, and zoledronic acid, and wherein the control sample has less than 2.5 copies of the c-MAF gene as measured using FISH.
A method for the treatment of a subject having breast cancer comprising determining that said subject has non increased c-MAF amplification, copy number, or gain in a tumor sample with respect to a control sample, and administering to said subject an agent selected from the group consisting of:
- clodronate, ibandronate, and zoledronic acid, and wherein the control sample has less than 2.5 copies of the c-MAF gene as measured using FISH.
A method for the identification of a subject having breast cancer who will benefit from treatment with an agent selected from the group consisting of clodronate, ibandronate, and zoledronic acid comprising:
- i) quantifying the c-MAF gene copy number, amplification, or gain in a tumor sample of said subject and
- ii) comparing the copy number, amplification, or gain obtained in i) with a reference value, wherein the reference value is less than 2.5 copies of the c-MAF gene as measured using FISH,
- wherein said subject has not increased copy number, amplification, or gain with respect to said reference value, and administering to said subject a therapy selected from the group consisting of clodronate, ibandronate, and zoledronic acid.
Dependencies are inferred from the claim text.